It has been well established that glia have multiple roles in the nervous system which include the regulation of external potassium and the uptake of the excitatory amino acids glutamate and aspartate which are released from neurons into the extracellular space (Nicholls and Atwell, 1990; Barres, 1991; Kanai et al., 1993) . Several lines of evidence suggest that glial cells may also play important roles in releasing neurotransmitters. Schwann cells can release ACh following axotomy of motoneurons (Dennis and Miledi, 1974) . Retinal Mtiller cell depolarization stimulates the release of glutamate through a reversal of an electrogenie glutamate uptake carrier (Szwatkovski et al., 1990) . Depolarization causes the calcium-dependent release of the amino acid taurine from hippocampal glia (Philibert et al., 1988) . Hy-posmotic shock of cortical astrocytes stimulates cell swelling, an increase in internal calcium and a correlated release of the amino acids aspartate and taurine (Kimelberg et al., 1990; O'Connor and Kimelberg, 1993) . Since glial cell calcium levels are regulated by neurotransmitters (Reisner et al., 1989; CornellBell et al., 1990; Glaum et al., 1990; Charles et al., 1991; Cornell-Bell and Finkbeiner, 1991; Inagaki et al., 1991; Jensen and Chiu, 1991; McCarthy and Salm, 1991) , this has prompted us to ask whether the neuroligand bradykinin causes a calciumdependent release of excitatory amino acids (EAAs) from glial cells.
In the PNS, the nonapeptide bradykinin is released from its precursors, the kininogens, by the action of the enzyme kallikrein in response to trauma (Dray and Perkins, 1993) . Bradykinin is known to mobilize calcium from inositol 1,4,.5trisphos-phate (IP,)-sensitive calcium stores in several cell types (for references, see Miller, 1987; Higashida and Ogura, 1991) . Since bradykinin can mobilize internal calcium, we have asked whether this agent can cause the release of excitatory amino acids from glial cells derived from the dorsal root ganglia. This study demonstrates that the neuroligand, bradykinin, mobilizes internal calcium from Schwann cells which stimulates a calcium-dependent release of the excitatory amino acids, glutamate and aspartate.
A brief account of this work has been reported previously (Liu et al., 1992; Jeftinija et al., 1994) 
Materials and Methods
Cell culture. Glial cultures from DRG were obtained by modification of the organotypic procedure (Gahwiler, 1984) . Following anesthesia with ether and decapitation, DRG from l-2 d old Sprague-Dawley rats were rapidly removed and washed in cold (4°C) oxygenated Gey's balanced salt solution (GBSS, GIBCO) modified by the addition of 2% glucose. The capsular sheet was carefully removed form the DRG to minimize fibroblast contamination. DRG were then embedded onto a glass coverslip inlaid in a 35 mm dish (for release studies) or into a glass bottomed dish (for calcium imaging) in a plasma-thrombin clot. Cultures were maintained at 36°C in a humidified 5% COJair atmosphere. The culture medium consisted of 25% horse serum (GIBCO), 25% Earle's Balanced Salt Solution (GIBCO), and 50% Basal Medium Eagle (GIBCO) containing 36 mM glucose. The central part of explants which contains neuronal cell bodies was removed from established cultures (4-7 d in culture). The residual glial cells were maintained for additional 72 hr when all experiments were performed. Neurites degenerated 24-48 hr following the removal of the central portion of explants leaving cultures containing only non-neuronal cells. The absence of neuronal elements was confirmed by immunocytochemistry.
In some experiments we enriched the number of Schwann cells in cultures using two methods (see Kleitman et al., 1992) . In the Wood method, DRG were cultured for 48-96 hr in the presence of cytosine arabinoside (Ara-C, 5 kg/ml). They were then transplanted to a new coverslip coated with chicken plasma. DRG explants were then cultured as described above to obtain DRG glia. In the Brockes method, DRG glia were incubated with Thy 1.1 antibody (hybridoma supernatant, American Type Culture, No. TIB103) and addition of rabbit complement (Sigma). Since Thy 1.1 is expressed on fibroblasts, but not on Schwann cells, this procedure leads to a complement mediated lysis of fibroblasts. In both culture methods, immunocytochemistry revealed that Schwann cells were enriched to >95%.
In some experiments we prepared fibroblast enriched culture using previously described procedure (Levison and McCarthy, 1992) . Immunocytochemistry revealed absence of neurons and Schwann cells and presence of about 5% GFAP positive cells.
Immunocytochemistry. Antibody visualization was accomplished by using a Vectastain ABC kit (Vector) and the nickel-enhanced DAB method (Hsu et al., 1981) . Immunocytochemistry was performed using antibodies directed against the synaptic proteins synaptophysin (1: 1000; clone 7.4a, provided by R. Jahn) and synaptotagmin (1:5000; clone 41.1, provided by R. Jahn), against glial fibrillary acidic protein (GFAP; 1:5000, ICN Immunobiologicals) and against the low-affinity NGF receptor (1:2000; 192-IgG, provided by E. M. Johnson, Jr.). Anti-synaptophysin, synaptotagmin, and anti-GFAP were found to be negative on DRG glia. Positive controls were performed with these antibodies using hippocampal neurons and astroglia and using DRG explants in which axons were maintained in culture.
EAA release. The coverslips with glial cultures were mounted into a 50 p,l perfusion chamber. A modified Ringer's perfusion solution containing (in II~M) NaCl 128, KC1 1.9, KH,PO, 1.2, CaCl, 2.4, MgSO, 1.3, NaHCO, 26, and glucose 10 (pH 7.4) bubbled with 95% O,, 5% CO, was used for constant flow through at a rate of 200 pl/min and 35-37°C. After an equilibration period of 40-60 min, samples of perfusate for amino acid determination were collected every minute. The amino acid content in samples was determined by high-performance liquid chromatography (HPLC) with fluorescence detection (Lindroth and Mopper, 1979) . Prior to injection, aliquots of samples were derivatized with o-phthalic aldehyde (OPA) 2-mercaptoethanol reagent (Pierce). Chromatography was performed on a 15 cm Microsorb-MV HPLC column (Rainin Instrument Co.) using a sodium acetate methanol gradient (pH 5.9). Bradykinin (10 nM; Sigma) and its antagonist (DArg", Hyp', P-This,8, D-Phe')-bradykinin (5 FM; Bachem Bioscience Inc.) were added to a perfusion solution. In control experiments we coadministered hydroxyproline (180 nM) together with bradykinin and determined that there is a 1 min lag time from initiation of the addition of an agent until it is collected for HPLC analysis due to dead-volume in the chamber. All figures for HPLC have been correspondingly corrected. Elevated K+ (50 II~M) solution for HPLC was prepared by modification of a Ringer's solution where NaCl was replaced by KCI.
Calcium imaging. Cells were loaded with fura-AM (4 PM; Molecular Probes) for 40-60 min at 37°C. One microliter of 25% (w/w) of Pluronic F-127 (Molecular Probes) was mixed with 1 ml of 4 FM Fura-AM ester solution. After washing, cells were kept for 30-60 min at 37°C to permit dye de-esterification. All experiments took place at 22-24°C. All image processing and analysis were performed using ratiometric software (QFM, Quantex Corp. or IMAGE-WI, v. 1.63g, Universal Imaging Corp.). Fura-fluorescence was excited by a xenon-arc lamp using 340 nm or 350 nm and 380 nm bandpass filters. Exciter filters were exchanged using a rotation filter wheel (Ludl 6-position). Neutral density filters were placed in the light path to prevent cell damage and to reduce photobleaching of fura-2. Fura-emission (510 DF 40nm filter) was collected using an SIT camera (Hammamatsu). Background subtracted, ratio images (340/380 nm or 350/380 nm) were used to calculate the [Ca2+], according to Equation 5 of Grynkiewicz et al. (1985) . Calibration was performed in situ (Thomas and-Delaville, 1991) using the Ca*+-ionoohore 4-bromo-A23187 (10 LLM. Molecular Probes). An estimate of aut&luorescence at each wavelkngih was achieved bi addition of MnCl, (20 mM). Cells were included in analysis if the first addition of bradykinin caused a [Ca*+], accumulation that was greater than 50% of the resting calcium level.
During calcium imaging, bradykinin and elevated K+ (50 mM) were applied to glia for 1 min by pressure ejection from a puffer pipette (opening diameter -2-3 km, 10 psi). All other drugs were uniformly applied to the bath by flow through. Repeated applications of bradykinin were spaced at 10 min intervals. In some experiments the second bradykinin application followed the first application after 30 min. Ryanodine (10 PM), caffeine (10 mM), and furosemide (5 mM) were applied 10 min prior to the second application of bradykinin while thapsigargin was applied to the bath 30 min prior to the second application of bradykinin. Thapsigargin (1 FM) was dissolved in dry DMSO. Control experiments with 0.1% (v/v) DMSO showed that DMSO did not affect the action of bradykinin. Normal saline contained (in 111~) NaCl 140, KC1 5, MgCl, 2, CaCl, 2, and HEPES 10 (pH 7.4). Calcium-depleted solution contained (in mM) NaCl 128, KC1 1.9, KH,PO, 1.2, CaCl, 0.2, EGTA 1, MgSO, 2.5, NaHCO, 26, and glucose 10 (pH 7.4). Elevated K+ saline was prepared by modification of normal saline where NaCl was replaced by KCl.
MAX CHELATOR (v. 5.6), written by Chris Patton at Stanford University, was used to calculate free extracellular calcium levels. The calculation includes a correction for extracellular Mg?+ ions.
Cell volume measurement. To determine whether bradykinin caused a shrinkage of cells in our studies we monitored cell volume using BCECF as described by Eriksson et al. (1992) . Cells were loaded by incubation in membrane permeable BCECF AM (10 FM) for 40-60 min, followed by 40 min for de-esterification. BCECF was excited at the pH-insensitive wavelength of 440 nm. The emission intensity (5 10 DF 40 nm bandpass) was monitored with a SIT camera. When cells swell, BCECF is diluted, reducing the fluorescent intensity detected. We confirmed that this approach effectively detected volume changes in our studies by applying hyposmotic saline that was made by removing 50 mM of NaCl from our standard saline (see above).
Results
Bradykinin stimulates excitatory amino acid release from dorsal root ganglia Schwann cells Primary glial cultures of dorsal root ganglia (DRG) were obtained using a modification of the organotypic procedure (Gabwiler, 1984) . Dorsal root ganglia were cultured on coverslips to permit neurite extension and migration of glial cells. After cultures were established, the central portion of the ganglionic explant, which contains neuronal cell bodies, was removed from the culture. During the next 48 hr the residual neurites degenerated leaving a neuron-free glial cell culture. The release of EAAs from these cultures was assayed using HPLC on the superfusate. The basal release of glutamate and aspartate into superfusate produced levels of 26 + 2 nM (mean t-SEM; n = 13) and 6 2 1 nM, respectively. Addition of bradykinin caused a dose-dependent increase in release of the EAAs glutamate and aspartate from glial cultures. The threshold concentration of bradykinin was 1 nM; 10 nM bradykinin caused a greater than ninefold increase in the release of glutamate to 239 -C 42 nM and a greater than threefold increase in aspartate to 21 5 3 nM (n = 12; Fig. lA,B) . A second application of bradykinin (n = 12) similarly caused EAA release, although the magnitude of this response was attenuated (Fig. lA,B ). This action is receptormediated since the B, receptor antagonist, (D-Arg", Hyp3, P-Thi5.8, D-Phe7)-bradykinin (5 PM), reversibly blocked the stimulatory action of bradykinin (n = 6; Fig. 1C ). While bradykinin stimulated the release of glutamate and aspartate from glial cultures it did not significantly affect the release of serine. The basal level of serine was 14 2 2 nM compared to 16 -C 2 nM in the presence of bradykinin (n y 13; p > 0.5). These data demonstrate that the nonapeptide bradykinin potently causes the selective release of the EAAs glutamate and aspartate from DRG glia.
The cell types present in the glial cultures derived from DRG was examined using immunocytochemistry. We confirmed that glial cultures were neuron-free by using antibodies against the synaptic proteins synaptophysin and synaptotagmin. In these cultures immunoreactivity for these two synaptic proteins was absent while neurons were immunopositive in separate cultures. An antibody against glial fibrillary acidic protein was negative in DRG glial cultures. However, using an antibody against the low-affinity NGF receptor, characteristically expressed in Schwann cells localized distal to the site of axotomy, but not in surrounding fibroblasts (Taniuchi et 2) . Therefore the predominant glial cell type in these DRG cultures is Schwann cells. As fibroblasts are likely to be a contaminating cell type in these cultures, we modified our techniques to enrich specifically in Schwann cells. Purified populations of Schwann cells (>95% of cells) were obtained by the Wood (n = 6) and Brockes (n = 6) methods (see Kleitman et al., 1992) . These cultures showed similar increases of the EAAs glutamate and aspartate in the superfusate after application of bradykinin. Bradykinin increased the glutamate levels in the superfusate from a basal level of 127 + 9 nM and 35 ? 7 IIM to 465 ? 23 nM and 123 t 16 nM The Journal of Neuroscience, August 1995, 75(8) 5833 using the Brockes and Wood methods, respectively. Fibroblast enriched cultures showed no significant increase in glutamate release after application of bradykinin (basal level 179 ? 17 nM; after bradykinin 226 + 23 nM; n = 4; p > 0.2). However, subsequent application of hyposmotic saline caused increase of glutamate in superfusate from a basal level of 160 -+ 37 nM to 1074 + 143 nM (n = 4; p < 0.02). We therefore conclude that the nonapeptide, bradykinin causes the release of the amino acids glutamate and aspartate from DRG Schwann cells.
Bradykinin mobilizes calcium in dorsal root ganglion Schwann cells The release of neurotransmitter at neuronal synapses is calcium dependent. To ask whether calcium might play a role in bradykinin-induced EAA release from DRG Schwann cells, we used ratiometric imaging techniques to monitor glial calcium levels. Cells were loaded with the membrane permeant calcium indicator fura-AM. Glia were imaged at low plating density, where they did not form a confluent monolayer. In resting conditions, the cytoplasmic calcium level of glia was 102 2 2 nM (n = 136). Bradykinin (10 nM) reliably raised the cytoplasmic level of free calcium in 72% of cells tested (n = 136 of 188). This increase of intracellular calcium reached the peak level of 747 2 24 nM (n = 136; Fig. 3A ) about 20 set after the onset of bradykinin application and was sustained for several minutes. In all subsequent experiments, we have reported the calcium levels for only those cells that responded to bradykinin. These bradykinin responsive cells had the morphology of Schwann cells. In some experiments we performed immunocytochemistry following calcium imaging using the antibody directed against the lowaffinity NGF receptor which is present in Schwann cell cultures. Immunocytochemistry demonstrated that those cells that responded to bradykinin with an elevation of internal calcium were immunopositive with the antibody directed against the low-affinity NGF-receptor (n = 22 of 22 cells). Therefore, bradykinin elevates internal calcium levels in Schwann cells in a manner temporally coincident with the timing of release of glutamate and aspartate.
Repeated applications of bradykinin reliably elevated calcium levels in Schwann cells (Fig. 3B) . The B, receptor antagonist (D-Argo, Hyp', P-This,*, D-Phe')-bradykinin (5 p,M), reversibly attenuated the stimulatory action of bradykinin on calcium mobilization. In the presence of the B, receptor antagonist, the average resting calcium level (107 + 3 nM) was moderately increased by application of bradykinin (15 1 + 11 nM; IZ = 32). However, after washout of the antagonist, bradykinin increased the cytoplasmic calcium level to 480 -C 24 nM (n = 32), a value significantly greater than in the presence of the B, receptor antagonist (Scheffk's test, p < 0.001).
Removal of external calcium from the bathing medium did not prevent the initial calcium mobilizing action of bradykinin (Fig. 3C ). Cells were bathed in a calcium-depleted saline containing 0.2 mM calcium with the addition of 1 mM EGTA to yield an estimated free extracellular calcium level of 24 nM. We found that it was necessary to have some calcium in the bathing medium otherwise cells detached from the culture substrate. In this calcium-depleted saline, bradykinin elevated cytoplasmic free calcium from 98 ? 2 nM to 713 ? 38 nM (n = 36). However, subsequent additions of bradykinin in calcium-depleted bathing medium had little calcium mobilizing action (n = 36 and IZ = 23 for the second and third applications, respectively; Fig. 3C ). These data suggest that bradykinin mobilizes calcium Figure 2 . DRG glia are immunopositive for the low-affinity NGF receptor. A shows a phase-contrast microgiaph of a field of DRG glia. Immunocytochemistry was performed on cultures using an antibody specific for the lowaffinity NGF-receptor which is expressed in Schwa& cells after axotomy. B shows a bright-field image of the same cells. Most of the glia are immunopositive indicating that they are Schwann cells.
from internal stores and that these stores must refill with calcium ture to prevent reloading of internal stores with calcium. Addifrom the extracellular medium.
tion of thapsigargin alone caused a transient increase in calcium Calcium mobilization from an internal store is further supported by observations using thapsigargin, an inhibitor of the from 90 '-c 5 to 320 2 42 nM (n = 15; Student's t test, p < Ca*+-ATPase of internal calcium stores. Following the first ad-0.0001). In the presence of thapsigargin, a second application of dition of bradykinin, thapsigargin (1 FM) was added to the culbradykinin failed to mobilize internal calcium as compared to matched control cells which were incubated in the DMSO carrier In (A) a focal application of bradykinin (BK, 10 nM) elevates DRG glial calcium level to a peak 20 set after the onset of application. During sustained application of bradykinin, glial calcium is maintained at a stable elevated plateau from basal calcium level (dashed line). In B repeated applications of bradykinin (10 nM) caused repeated elevations of glial cytoplasmic calcium levels. In C the external calcium was reduced by exchange of normal saline for calcium-depleted saline. In this saline bradykinin was able to elevate calcium from its resting level indicating that calcium is mobilized from internal stores. However, a second and third addition of bradykinin had little effect on internal calcium levels (compare C with B). Bars represent means 2 SEM. saline (n = 26; Scheffk's test, p < 0.001; Fig. 4 ) supporting the notion that bradykinin mobilizes calcium from an internal store.
To determine the type of internal calcium store which bradykinin acts on, we added ryanodine, which can block the release of calcium from the caffeine-sensitive calcium store. Ryanodine (10 PM) did not affect the calcium mobilizing action of repeated applications of bradykinin (n = 21 and n = 20 for the second and third applications, respectively; Scheff& test, p > 0.25; Fig.  4C ). Furthermore, the sustained presence of caffeine (10 mu) did not affect the calcium-mobilizing action of bradykinin (n = 23; Scheffk's test, p > 0.25; Fig. 4C ). Thus, we conclude that bradykinin predominantly mobilizes calcium from a ryanodine/ caffeine-insensitive internal calcium store. This suggests that bradykinin's actions are mediated through an IP,-sensitive calcium store. This is consistent with other studies which have shown that bradykinin causes phosphoinositide hydrolysis in oligodendrocytes and astrocytes (Ritchie et al., 1987) .
Excitatory amino acid release from Schwann cells is calcium dependent
Calcium-imaging data raise the possibility that bradykinin stimulates EAA release through mobilizing internal calcium. To test whether calcium is necessary for glutamate release we determined whether multiple applications of bradykinin caused glutamate release in calcium-depleted saline. Consistent with the ability of bradykinin to mobilize calcium in calcium-depleted saline the first bradykinin application stimulated the release of glutamate from glial cultures (n = 6, Fig. 5A ) in calcium-depleted saline. However, a second application of bradykinin in calcium-depleted saline did not cause significant glutamate release (n = 6; Student's t test, p > 0.5; Fig. 5A ). To further test the calcium hypothesis for glutamate release, we incubated glial cultures for 30 min in 50 PM BAPTA-AM in calcium-containing saline. This membrane permeant calcium chelator blocked the stimulatory action of bradykinin on glutamate release (n = 6; Student's t test, p > 0.3; Fig. 5B ).
As a critical test of the calcium hypothesis we exposed cultures to the calcium-ionophore, ionomycin, in calcium-containing saline. Ionomycin transports Ca*+ across a variety of lipid bilayers, without the requirement of specific constituents of biological membranes (Blau and Weismann, 1988) . It can thus be expected that it provides a uniform entry of Ca2+ across the entire plasma membrane. Addition of ionomycin (5 FM) stimulated the release of both glutamate (n = 6; Student's t test, p < 0.025; Fig. 5C ) and aspartate (data not shown). Ionomycin was without stimulatory effects when glia were bathed in calciumdepleted saline (n = 6; Student's t test, p > 0.9; Fig. 5C ). Taken together, these data demonstrate that calcium is mobilized in Schwann cells coincident with the timing of EAA release. This calcium mobilization is both necessary and sufficient for stimulating the release of EAAs from Schwann cells.
p-Chloromercuriphenylsulfonic acid does not irlhibit EAA release from Schwann cells
Glutamate can be released from cells during depolarization through the reversal of an electrogenic glutamate uptake carrier (Szwatkowski et al., 1990) . To determine whether this mechanism might regulate glutamate release from DRG Schwann cells, we depolarized them using elevated potassium saline. Application of elevated K+ (50 mM) did not cause a change in Schwann cells calcium levels (n = 27; Student's t test, p > 0.1) nor stimulated EAA release from DRG glia. In control conditions we detected 48 5 7 nM glutamate in the superfusate. Following addition of 50 mM K+ saline we detected 46 ? 6 nM glutamate (n = 6; Student's t test, p > 0.7). The lack of glutamate release from DRG glia during the application of elevated K+ saline is not consistent with a role for the reversal of a glutamate uptake carrier in mediating the bradykinin-induced release of EAAs from DRG Schwann cells. Furthermore, addition of the glutamate transporter inhibitor p-chloromercuriphenylsulfonic acid (p-CMPS; 50 FM) did not reduce the bradykinin stimulation of glutamate and aspartate release. However, consistent with previous observations using glutamate transporter inhibitors (Balcar and Johnston, 1971; Isaacson and Nicoll, 1993) , p-CMPS did elevate the basal level of glutamate in the bathing medium. Time (min) normal Caz+ Caz+-depleted Time (min) Figure 5 . Calcium is necessary and sufficient for glutamate release from DRG glia. The first application of bradykinin (BK) caused glutamate release from glial cells bathed in calcium-depleted saline. However, a second application of bradykinin failed to produce significant release of glutamate (A). After incubation with BAPTA-AM (50 PM; Molecular Probes) for 30 min, cells were unable to release glutamate in response to bradykinin showing that increase of intracellular calcium is necessary for glutamate release (B). Sufficiency of calcium to induce glutamate release has been established using ionomycin. Cells released glutamate after application of ionomycin when bathed in normal calFium saline, but -not when bathed in calcium-depleted saline (C). In both calcium-depleted and BAPTA treated cells, there was a slight augmentation of basal glutamate levels in the supernatant. Points represent means r+_ SEM.
EAA release from Schwann cells is not mediated by a cell swelling-dependent mechanism Hyposmotic media cause a swelling-dependent release of aspartate and taurine from cortical astrocytes (Kimelberg et al, 1990 ). This release is sensitive to anion transport inhibitors. We determined whether Schwann cells have a similar sensitivity by incubating them in furosemide (5 mM). Bradykinin-induced release of glutamate was reduced by 98% (n = 5; p < 0.001, Student's t test) in the presence of furosemide (Fig. 6A) . To ask whether furosemide inhibits glutamate release by acting at the Figure   6 . Furosemide, an anion transporter blocker, inhibits bradykinin-induced glutamate release from Schwann cells. In A an application of bradykinin in presence of furosemide (5 mM, Sigma) did not cause glutamate release from Schwann cells. In parallel, bradykinin-induced calcium mobilization is greatly attenuated by the presence of furosemide in bathing medium (B). Relative Ca*+ mobilization is expressed as percentage values of [Ca*+], accumulation (peak value subtracted from resting; ACa) during the second application of bradykinin (ACa,) compared to the first (ACa,) (relative calcium mobilization = ACa,/ACa, X 100).
C and D, BCECF-loaded Schwann cells were used to determine the effect of bradykinin on cell volume. BCECF emission intensity, in response to excitation at 440 nm, was used to monitor cell volume. In C time-lapse of a single BCECF loaded Schwann cell stimulated with hyposmotic saline and bradykinin is shown. Addition of hyposmotic saline significantly reduced the fluorescence intensity which corresponds to cell swelling (C, D). Quite the contrary, subsequent addition of bradykinin at a concentration of 10 nM, which stimulates calcium
The Journal of Neuroscience, August 1995, 75(8) 5837 level of the calcium signal we determined the effect of furosemide on bradykinin-induced calcium mobilization. Using repeated applications of bradykinin (see Fig. 4 for protocol) we found that addition of furosemide (5 EIM) significantly attenuated (n = 43; p < 0.001, Student's t test) the ability of the second application of bradykinin to mobilize calcium (Fig. 6B ).
Since furosemide reduces bradykinin-induced calcium mobilization, it is not clear whether the release mechanism per se is sensitive to this anion transport inhibitor as has been demonstrated in astrocytes in response to hyposmotic media (Kimelberg et al., 1990) . Therefore, to further test whether bradykinin stimulates glutamate release from Schwann cells through a cell swelling mechanism we monitored cell volume during bradykinin application. Schwann cells were loaded with BCECF and the fluorescence emission was monitored in response to excitation at the pH-insensitive wavelength of 440 nm. Sequential additions of hyposmotic media repeatedly and reversibly reduced the intensity of BCECF fluorescence demonstrating that this method can detect swelling of Schwann cells ( Fig. 6C,D ; n = 36; p < 0.001, paired t test). Application of bradykinin caused a significant increase in the intensity of BCECF fluorescence which corresponds to decrease of cell volume ( Fig. 6C,D ; 2.0 5 0.3%; n = 36; p < 0.001, paired t test). As bradykinin does not cause swelling (n = 36; p > 0.25, paired t test), it does not liberate EAAs from Schwann cells through a previously described cell swelling-dependent release mechanism.
Discussion
Our data demonstrate that the release from Schwann cells of the excitatory amino acids, glutamate and aspartate, is regulated by the neuroligand bradykinin. Bradykinin causes the mobilization of calcium from internal stores in Schwann cells within seconds of addition to cultures. This calcium elevation is sustained for several minutes. In parallel cultures, bradykinin releases glutamate and aspartate within one minute of delivery of bradykinin to the superfusion chamber. Thus, the bradykinin-induced calcium elevation is temporally coincident with the release of EAAs raising the possibility that it is required for EAA release. To test this hypothesis, we asked whether calcium elevations are both necessary and sufficient for EAA release. When we bypassed the bradykinin receptor and directly elevated internal calcium using calcium ionophore EAA release was stimulated as long as a source of calcium was present. The calcium-elevation stimulated by bradykinin was also shown to be necessary for the release of EAAs. When calcium mobilization was blocked using BAPTA-AM or by removing external calcium during repeated bradykinin applications, bradykinin no longer stimulated the release of EAAs from Schwann cells. Taken together these data demonstrate that bradykinin mobilizes internal calcium in Schwann cells which is both necessary and sufficient to stimulate the release of glutamate and aspartate.
A key issue to address is the nature of the release mechanism that is responsible for EAA liberation from Schwann cells (Att elevations and EAA release, significantly increased the fluorescence intensity. A second addition of hyposmotic saline demonstrated, however, that these cells were still able to respond with increase in cell volume. Points (in A) and bars (in B and D) represent means 2 SEM. Student's t test was used to determine the significance of furosemide effect on bradykinin-induced calcium mobilization, while in (D) a paired t test was used. Significance was found to be p < 0.001 (*). (Szatkowski et al., 1990) . Alternatively, hyposmotic medium causes cell swelling which stimulates EAA release that is sensitive to the anion transport inhibitor, furosemide (B) (Kimelberg et al., 1990) . Since Schwann cell depolarization does not induce EAA release, the glutamate transport inhibitor p-CMPS does not inhibit bradykinin stimulated EAA release and since bradykinin does not induce swelling of Schwann cells, neither of these release mechanisms is likely to be responsible for neuroligand-induced EAA release. The properties of the bradykinin induced EAA release mechanism of Schwann cells are summarized in (C). Bradykinin acts on a B, receptor which leads to a furosemide-sensitive elevation of calcium. Calcium ions, liberated from internal stores, are both necessary and sufficient to stimulate EAA release from Schwann cells. Further studies are required to determine whether this calcium-dependent release mechanism is similar to the neuronal vesicular release mechanism of synaptic transmission. twell, 1994; Smith 1994 ). This release mechanism may take at least three forms (Fig. 7) . Glutamate can be released through the reversal of a glutamate transporter (Fig. 7A) . Retinal Miiller cells, for example, release glutamate in a calcium-independent fashion in response to elevated [K+] , due to the reversal of the normal glutamate uptake mechanism (Szwatkovski et al., 1990) . This mechanism probably does not account for the release of EAAs in response to bradykinin in DRG Schwann cells since the action of bradykinin is calcium dependent, glutamate release is not stimulated by depolarizing stimuli which would reverse the glutamate uptake carrier and p-CMPS does not block bradykinin-induced release of EAAs.
In cortical astrocytes hyposmotic medium causes cell swelling and the consequent release of glutamate, taurine, and aspartate (Kimelberg et al., 1990; O'Connor and Kimelberg, 1993; Fig. 7B ). An anion transport blocker, furosemide, reduces cell swelling dependent release from cortical astrocytes (Kimelberg et al., 1990) . This raises the hypothesis that bradykinin causes cell swelling which in turn stimulates EAA release from Schwann cells. We therefore tested the action of furosemide on EAA release. In Schwann cells furosemide reduced bradykinin-stimulated calcium mobilization and EAA release. Since furosemide significantly modified bradykinin-induced calcium signaling this experiment did not allow us to determine whether the cell swelling dependent release mechanism is utilized. Therefore, we directly measured cell volume and asked whether bradykinin induces cell swelling. Using BCECF our data clearly demonstrated that while hyposmotic media induced swelling of Schwann cells, bradykinin did not. These data are not consistent with bradykinin inducing the release of EAAs through the previously described volume regulated mechanism (Kimelberg et al., 1990; O'Connor and Kimelberg, 1993) . Furthermore, these previous studies have shown that cell swelling induced EAA release is calcium independent, while calcium is both necessary and sufficient for bradykinin-induced EAA release from Schwann cells.
A third potential mechanism of bradykinin-stimulated EAA release is through a membrane/vesicle release mechanism similar to that of neurons. Cultures were free of immunoreactivity for the synaptic proteins synaptophysin and synaptotagmin while axons of DRG explants (separate cultures; data not shown) were immunopositive for these synaptic proteins. Thus, proteins characteristic of neuronal transmitter release apparatus are absent in Schwann cells. However, these observations do not rule out quanta1 membrane release mechanisms since muscle (Dan and Poo, 1992) and fibroblasts (Adler et al., 1993) have been demonstrated competent to release neurotransmitters in a quanta1 fashion. Figure 7C summarizes our current understanding of the bradykinin-induced EAA release mechanism. Bradykinin, acting through a receptor, mobilizes internal calcium which is necessary and sufficient to stimulate EAA release from Schwann cells independent of cell volume changes. The nature of this calciumdependent release apparatus remains to be defined.
The regulated release of neurotransmitters from glia may be a widespread property. Stimulation of motoneurons leads to the elevation of calcium in the Schwann cells which surround the presynaptic terminal (Jahromi et al., 1992) . After denervation, Schwann cells have been shown capable of releasing ACh (Dennis and Miledi, 1974) . Depolarization of hippocampal astrocytes causes the calcium-dependent release of the amino acid taurine, but not glutamate (Philibert et al., 1988) . Recently, we demonstrated that glial cells from the cerebral cortex release aspartate and glutamate in response to bradykinin . Since many neurotransmitters utilized by the nervous system can mobilize calcium in glia (Reisner et al., 1989; Cornell-Bell et al., 1990; Glaum et al., 1990; Charles et al., 1991; Cornell-Bell and Finkbeiner, 1991; Inagaki et al., 1991; Jensen and Chiu, 1991; McCarthy and Salm, 1991) , it is possible that neurons have in addition to their fast neuron-neuron synaptic actions, a calcium mobilizing action on neighboring glia (Dani et al., 1992) which in turn leads to the release of other neurotransmitters from glia that may serve secondary roles in glia-neuronal transmission. In support of this possibility recent studies have demonstrated that glia can signal to neurons (Parpura, 1993; Charles, 1994; Nedergaard, 1994; Parpura et al., 1994) .
